Stocktoria
UNITED THERAPEUTICS Corp UTHR
UNITED THERAPEUTICS Corp financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2B | $2.9B | $2.3B | $1.9B | $1.7B | $1.5B | $1.4B | $1.6B | $1.7B | $1.6B |
| Gross profit | $2.8B | $2.6B | $2.1B | $1.8B | $1.6B | $1.4B | $1.3B | — | — | — |
| R&D expense | $550.0M | $481.0M | $408.0M | $322.9M | $540.1M | $357.7M | $1.2B | $357.9M | $264.6M | $147.6M |
| SG&A expense | $755.8M | $709.7M | $477.1M | $482.1M | $467.0M | — | — | $265.8M | $330.1M | $316.8M |
| Operating income | $1.5B | $1.4B | $1.2B | $979.7M | $555.9M | $593.6M | -$187.6M | $805.4M | $814.9M | $1.1B |
| Interest expense | — | — | $59.3M | $32.4M | $18.6M | $23.5M | $44.2M | $13.9M | $9.0M | $3.9M |
| Income tax | $379.2M | $343.9M | $289.5M | $223.3M | $118.1M | $124.1M | -$60.5M | $169.7M | $351.6M | $346.5M |
| Net income | $1.3B | $1.2B | $984.8M | $727.3M | $475.8M | — | — | — | — | — |
| EPS (diluted) | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 | $11.54 | $-2.39 | $13.39 | $9.31 | $15.25 |
| Operating cash flow | $1.6B | $1.3B | $978.0M | $802.5M | $598.2M | $755.7M | -$206.6M | $778.4M | $474.2M | $643.6M |
| Free cash flow | $1.0B | $1.1B | $747.6M | $663.7M | $477.4M | $696.4M | -$290.3M | $594.0M | $387.9M | $605.6M |
| Cash & equivalents | $1.6B | $1.7B | $1.2B | $961.2M | $894.8M | $738.7M | $738.4M | $669.2M | $705.1M | $1.0B |
| Inventory | $183.1M | $157.9M | $111.8M | $102.0M | $93.8M | $86.5M | $93.4M | $101.0M | $107.9M | $100.0M |
| Total assets | $7.9B | $7.4B | $7.2B | $6.0B | $5.2B | $4.6B | $3.9B | $3.4B | $2.9B | $2.3B |
| Total liabilities | $783.8M | $920.0M | $1.2B | $1.2B | $1.2B | $1.2B | $1.1B | $593.2M | $758.4M | $463.4M |
| Shareholders' equity | $7.1B | $6.4B | $6.0B | $4.8B | $4.0B | $3.4B | $2.8B | $2.8B | $2.1B | $1.9B |
Growth · year-over-year · Revenue CAGR 7.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +10.6% | +23.6% | +20.2% | +14.9% | +13.6% | +2.4% | -11.0% | -5.7% | +7.9% | +9.1% |
| Net income growth | +11.7% | +21.4% | +35.4% | +52.9% | — | — | — | — | — | — |
| EPS growth | +13.1% | +24.4% | +32.1% | +49.1% | -12.8% | — | -117.8% | +43.8% | -39.0% | +19.9% |
| Free cash flow growth | -3.7% | +44.5% | +12.6% | +39.0% | -31.4% | — | -148.9% | +53.1% | -35.9% | +81.9% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.